THOMAS J. HUDZIK, PH.D.

ALA BioPharma Consulting

*** ********** **.

Monroe, NJ 08831

224-***-****

ad20a7@r.postjobfree.com

ad20a7@r.postjobfree.com

SUMMARY

Seasoned, highly collaborative scientist with significant experience in leading and managing drug discovery and development programs in numerous therapeutic areas Strong record of scientific publications Proven track record of leadership of cross-functional teams that have delivered four candidate drugs into clinical development Contributor to multiple NDAs/BLAs and INDs Excellent communication and presentation skills Experience with large and small molecules, Preclinical through to post-market support Long service as NIH Grant Application Reviewer NIDA/NINDS.

Subject matter expertise in Abuse Potential Assessment and Abuse Deterrent Formulations, Efficacy and Safety Pharmacology, Animal Models development and application, CNS Pharmacology and Toxicology.

EDUCATION

MS / Ph.D. Neuroscience / Pharmacology, University of New Orleans, New Orleans, LA.

BA. Experimental Psychology, Rutgers College, New Brunswick, NJ.

PROFESSIONAL EXPERIENCE

ALA BioPharma Consulting link 2022-Present

Abuse potential assessments and 8-factor analyses for NDAs

DEA scheduling recommendations

Abuse deterrent formulations

Pharmacology and Toxicology consulting services

BlueRock Therapeutics, New York, NY 2020-2022

Senior Director – Translational Neurology

Leading translational research strategies for cell therapies

Leading cross-functional teams in advancement of cell therapies to clinic for neurological diseases

Supporting clinical development of cell therapy in Parkinson’s disease

Pharmacology/Toxicology Consultant for World Antidoping Agency 2011-Present

Participated on the Prohibited Substances List Committee.

Managed stakeholder queries

Followed and reported world doping trends

Generated annual prohibited substances list

Ran sub-teams on special topics

NIH: NIDA/NINDS Study Section Standing Member (substance use disorder treatments)

R01, UG/UH3 Proposal Reviewer 1998-2002; 2016-Present

R01

GlaxoSmithKline, Collegeville, PA 2017-2020

Scientific Leader

Led team of 5 safety pharmacologists assessing cardiovascular and central nervous system risk in both early and late portfolio.

Advised preclinical and clinical project teams on risk mitigation strategies

oOversaw internal and external studies supporting risk mitigation strategies

Led global efforts in automation of data capture and Robust Study Design for In Vivo Studies

Provided post-marketing support to FDA queries on older small molecules as well as the HIV portfolio.

Provided support for 2 FDA Advisory Committees (tuberculosis drug, oncology drug).

ALA Biopharma Consulting, Gurnee, IL 2016 – 2017

CEO and Senior Consultant

Assisted small and medium sized biotech in planning and preparation of Toxicology sections for Regulatory filings. (1 biologic, 2 small molecules)

Devised, carried out, (via CRO where appropriate) abuse potential assessment studies (8 small molecules) and populated the abuse potential sections of 3 small molecule NDAs.

Directed and monitored NHP toxicology studies.

AbbVie, North Chicago, IL 2010 - 2016

Pharmaceutical Research and Development.

Volweiler Research Fellow; Associate Director, Preclinical Safety Assessment

Program Leader - CNS Safety Advisory Group. Coordination of global preclinical and clinical strategy for undesired CNS effects of new chemical and biologic entities. Leader and participant in several inter-company safety pharmacology working groups, including cross-pharma-FDA working group on abuse potential assessment. Promoted to Volweiler Research Scholar in 2014.

oDeveloped risk mitigation strategies for convulsant effects, suicidality, abuse potential.

oDeveloped and implemented (via CRO) abuse liability strategies for 3 programs.

Toxicology Project Representative: Discovery and development programs, supporting Neuroscience, GI, Immunology, Oncology, and HBV, Renal therapeutic areas.

oOversaw internal and external studies supporting programs as study director & study monitor.

oDeveloped regulatory strategies and wrote toxicology sections for INDs for cognitive enhancers, novel analgesics, substance use disorder treatments, reproductive health products, schizophrenia and bipolar candidates.

oWrote toxicology and contributed to Integrated Safety Summary for NDAs for 3 novel medications.

AstraZeneca, Wilmington, DE 2000 - 2010

Project Director

Directed cross-functional teams of chemists, pharmacologists, in delivering candidate drugs into development. Co-managed late discovery/ early development portfolio with a cross-functional team. Liaised between development and discovery. Led Patient Insight program, allowing for dialog between customers (psychiatric patients) and scientists.

Supervised a team of PhD and MS level pharmacologists – predictive pharmacology.

Principal Investigator II, AstraZeneca (Worcester, MA) 1997-2000

Duties as below and in addition, discovery representative for early drug development teams. Worked closely with experimental medicine to design and implement proof of principle/concept studies.

Completed pharmacology portion of 3 US and European INDs; initiated and maintained a clinical collaboration with NIMH.

Principal Investigator, Early Project Leader, Astra Arcus 1994-1997

Responsibilities as below; in addition, responsibility for evaluation of potential biotech collaborations and in-licensing opportunities. Course coordinator (1998): St. John Fisher College, Pharmacology for Nurse Practitioners.

Responsibilities as below; coordinated target evaluation and validation. Supervised 2 Research Assistants.

Senior Research Scientist, Fisons Pharmaceuticals /Astra Arcus USA 1992-1994

(Rochester, NY)

Supervised and conducted in vivo and in vitro experiments supporting research, development and safety of antiepileptics, cognitive enhancers, anti-ischemics, neuroleptics, antidepressants, anxiolytics. Biology Database Administrator.

Supervised 3 Research Assistants, and 8 co-op students. Trained 1 postdoctoral fellow.

University of Arkansas for Medical Sciences 1990 - 1992

Postdoctoral Research Fellow: Research on cognitive effects of drugs of abuse.

University of Arkansas at Little Rock 1991

Instructor, Physiological Psychology

University of New Orleans 1988 - 1990

Instructor, General Psychology

PROFESSIONAL ORGANIZATIONS

World Anti-Doping Agency (WADA) List Committee since 2011

Behavioral Pharmacology Society

Society for Neuroscience

College on Problems of Drug Dependence (Committees)

Under-Represented Populations

Animals in Research

Academia-Industry

Membership

CONSORTIA (2011-Present)

HESI – Biomarkers of Neurotoxicity

Industry/FDA/NIDA - Preclinical and Clinical Abuse Liability Assessment (CCALC)

NC3Rs - In Vitro Models of Neurotoxicity

IQ-Consortium- Treatment-Emergent Suicidal Behavior

IQ-Consortium - Cross-species translation of convulsion risk

MANUSCRIPT REFEREE

Neuroscience and Biobehavioral Reviews

Journal of Pharmacol. and Exper. Therapeutics

Psychopharmacology Pain

Neuropharmacology Br. J. Pharmacol;

E.U. J. Pharmacol J Pharm Tox Methods

Regulatory Tox and Pharm

Pharmacology, Biochemistry and Behavior

PROFESSIONAL REFERENCES

Contact information upon request

RECENT HIGHLIGHTED PUBLICATIONS

Hudzik, TJ and Shram, M (2024 in preparation). Assessment of Physical Dependence: a translational perspective.

Hudzik, TJ et al., (2023) Cannabis and Sport: A World Antidoping Perspective. Addiction, Addiction, Volume118, Issue11 Pages 2040-2042. https://doi.org/10.1111/add.16315

Hudzik, TJ (2023) Reevaluating the assessment of physical dependence. Design and statistical analysis of abuse potential studies. FDA-CCALC-NIDA conference, Bethesda, MD. https://apdialogue2023.com/

Jones, J. D., Varshneya, N. B., Hudzik, T. J., & Huhn, A. S. (2021). Improving Translational Research

Outcomes for Opioid Use Disorder Treatments. Current Addiction Reports, 8(1), 109-121.

Hudzik, Thomas J. "Self-Injurious Behavior in Clinical and Preclinical Populations: Description, Etiology, and Management." In Advanced Issue Resolution in Safety Pharmacology, pp. 131-141. Academic Press, 2019.

de Zafra, C. L. Z., Markgraf, C. G., Compton, D. R., & Hudzik, T. J. (2018). Abuse liability assessment for biologic drugs–All molecules are not created equal. Regulatory Toxicology and Pharmacology, 92, 165-172.

Goody, S.M.G., Cannon, K.E., Liu, M., Kallman, M.J., Martinolle, J.P., Mazelin-Winum, L., Giarola, A., Ardayfio, P., Moyer, J.A., Teuns, G. and Hudzik, T.J., 2017. Considerations on nonclinical approaches to modeling risk factors of suicidal ideation and behavior. Regulatory toxicology and pharmacology, 89, pp.288-301.

Bespalov A, Müller R, Relo A and Hudzik T. 2016. Drug Tolerance: A Known Unknown in Translational Neuroscience. Trends in Pharmacological Sciences, 37(5), doi: 10.1016/j.tips.2016.01.008.

Marek, G.J., Day, M. and Hudzik, T.J., 2015. The utility of impulsive bias and altered decision-making as predictors of drug efficacy and target selection: Rethinking behavioral screening for antidepressant drugs. Journal of Pharmacology and Experimental Therapeutics, pp.jpet-115. doi:10.1124/jpet.115.229922

Markgraf C, Hudzik, T. and Compton, D. eds., 2015. Nonclinical Assessment of Abuse Potential for New Pharmaceuticals. Academic Press. Elsevier. ISBN-13: 978-0124201729.

RECENT INVITED PRESENTATIONS

Study design considerations and thoughts on best practice for nonclinical physical dependence studies. Cross-Company Abuse Liability Council / FDA / NIDA Joint Scientific meeting. Bethesda, MD, 2018.

Increasing the predictive power of animal models in the CNS Space. Neuropsychiatric Drug Development Summit, Boston, 2018.

Epidemiology of the U.S. Opioid Crisis. American College of Toxicology, 2018.

Animal Models: Are They Giving Us What We Need? Safety Pharmacology Society, Vancouver, 2016.

Cannabinoids: Pharmacology and Toxicology. Midwest Society for Toxicology, 2016.

Abuse Potential Assessment of ABT-126, and 7 nicotinic agonist. College on Problems of Drug Dependence, 2016.

Assessment of the potential for abuse of new pharmaceuticals. Rosalind Franklin Medical College Seminar speaker, 2015

Regulatory Interactions in abuse potential assessment strategies. Safety Pharmacology Society. Prague, 2015.

The Science and Regulatory Compliance of the Assessment of the Abuse Potential of New Pharmaceuticals. Japanese Society of Toxicology, 2015.

Identifying Predictive Animal Models. World CNS Summit, Boston, 2015.

Considerations for Abuse Liability Assessment for Large Molecules. Joint NIDA-FDA-CCALC Science of Abuse Liability Meeting. Bethesda, MD, 2015.

Bibliography: https://www.ncbi.nlm.nih.gov/myncbi/14yToxUKrLdkb/bibliography/public/

PUBLICATIONS/PRESENTATIONS/ABSTRACTS/PATENTS

Patel MV, Peltier, HM, Matulenko MA, Koenig JR, Scanio MJ, Gum TJ, El-Kouhen, O, Fricano, M, Lundgaard, G, Neelands T, Hutzik T,. Girant G, Kort ME. (2022) Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and Analogs as Small Molecule Nav1.7/ Nav1.8 Blockers for the Treatment of Pain. Bioorgainc and Medicinal Chemistry (in press).

Hudzik, T. J., Patel, M., & Brown, A. (2021). β2 Adrenoceptor agonist activity of higenamine. Drug Testing and Analysis, 13(2), 261-267.

Mosnaim AD, Wolf ME, O’Donnell J & Hudzik t(2019) β-Phenylethylamine and various monomethylated and para-halogenated analogs. Acute toxicity studies in mice, Drug and Chemical Toxicology, DOI: 10.1080/01480545.2018.1551899

Hudzik, Thomas J., et al. "Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR)." Pharmacology Biochemistry and Behavior 158 (2017): 22-31.

Backes, K., Lorenz, H., Laplanche, L., Hudzik, T.J., Potschka, H. and Hempel, K., (2016). A retrospective evaluation of species-specific sensitivity for neurological signs in toxicological studies: Is the dog more sensitive than the non-human primate? Toxicology Letters, 243, pp.78-87.

Richards, E.M., Mathews, D.C., Luckenbaugh, D.A., Ionescu, D.F., Machado-Vieira, R., Niciu, M.J., Duncan, W.C., Nolan, N.M., Franco-Chaves, J.A., Hudzik, T. and Maciag, C., 2016. A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. Psychopharmacology, pp.1-12. (doi:10. 1007/ s00213-015-4195-4)

Cross, A.J., Widzowski, D., Maciag, C., Zacco, A., Hudzik, T., Liu, J., Nyberg, S. and Wood, M.W., 2016. Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models. British Journal of Pharmacology, 173(1), pp.155-166.

Roberts, R.A., Aschner, M., Calligaro, D., Guilarte, T.R., Hanig, J.P., Herr, D.W., Hudzik, T.J., Jeromin, A., Kallman, M.J., Liachenko, S. and Lynch, J.J., 2015. Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward.Toxicological Sciences,148(2) pp.332-340.

Mosnaim, Aron D., Thomas Hudzik, and Marion E. Wolf. 2015. Behavioral Effects of [beta]-Phenylethylamine and Various Monomethylated and Monohalogenated Analogs in Mice Are Mediated by Catecholaminergic Mechanisms. American Journal of Therapeutics (2015).

Markgraf, C., Hudzik, T. and Compton, D. eds., 2015. Nonclinical Assessment of Abuse Potential for New Pharmaceuticals. Academic Press. ISBN-13: 978-0124201729

Compton, D. and Hudzik, T. Neurochemistry of abuse liability assessment and primary behavioral correlates. In: Markgraf, C., Hudzik, T. and Compton, D. eds., 2015. Nonclinical Assessment of Abuse Potential for New Pharmaceuticals. Academic Press. ISBN-13: 978-0124201729.

Suicide: Phenomenology and Neurobiology K. Cannon and TJ Hudzik (eds) (2014) ISBN 978-3-319-09963-7 ISBN 978-3-319-09964-4 (eBook) DOI 10.1007/978-3-319-09964-4

Springer International Publishing Switzerland 2014.

Hudzik, TJ and Marek, G. “Neurological Disease and Suicidal Behavior” In: K. Cannon and TJ Hudzik (eds) Suicide: Phenomenology and Neurobiology Springer, 2014.

Aron D. Mosnaim, Ph.D., Thomas Hudzik, Ph.D. and Marion E. Wolf, M.D. (2014) Analgesic effects of phenyethylamine and varous methylated derivates in mice. J. Neurochemical Research. DOI 10.1007/s11064-014-1354-7).

Hudzik, TJ, Pietras, M., Caccese, M, Bui, K, Yocca, FY, Paronis, C, and Swedberg, MDB (2014). Safety Pharmacology of the Delta Opioid Agonist AZD2327 I : Further Characterization of its Behavioral Effects and Abuse Potential. Pharmacol. Biochem. Behav 124: 48-57, 2014

Aron D. Mosnaim, Ph.D., Owen H. Callaghan, Ph.D., Thomas Hudzik, Ph.D. and Marion E. Wolf, M.D. 2013. Rat Brain-uptake index for phenylethylamine and various monomethylated derivatives. Neurochemical Research. Online DOI 10.1007/s11064-013-0988-1

T.J. Hudzik, Ana Basso, Janel M. Boyce-Rustay, William Bracken, Kaitlin E. Browman Karla Drescher, Tim Esbenshade, Lise I. Loberg, James J Lynch III and Jorge Brioni Abuse Liability Assessment of ABT-288, a selective histamine H3 receptor antagonist . Psychopharmacology 228:187-197, 2013. Online DOI 10.1007/s00213-013-3027-7

McCauley, John P. Jr., Cathy L. Dantzman, Megan M. King, Glen E. Ernst, Xia Wang, Kelly Brush, William E. Palmer, William Frietze, Donald W. Andisik, Valerie Hoesch, Kenneth Doring, James Hulsizer, Khanh H. Bui, Jay Liu, Thomas J. Hudzik, Steven S. Wesolowski. Multiparameter exploration of piperazine derivatives as d-opioid receptor agonists for CNS indications. Bioorganic & Medicinal Chemistry Letters (2012) 22:1169–1173

Dantzman, CL, Megan M King, Glen E Ernst, Xia Wang, John P McCauley Jr, Donald W Andisik, Kelly Brush, Khanh H Bui, William Frietze, Valerie Hoesch, Jay Liu, William E Palmer, Nathan Spear, Thomas J Hudzik, Steven S Wesolowski. 4-Piperidin-4-ylidenemethyl-benzamides as δ-opioid receptor agonists for CNS indications: Identifying clinical candidates. Bioorganic & Medicinal Chemistry Letters 2012, Volume 22, Issue 2, 15 January 2012, Pages 1174–1178.

Elmore, C.S., Kelly Brush, Magnus Schou, William Palmer, Peter N. Dorff, Mark E. Powell, Valerie Hoesch, James E. Hall Thomas Hudzik, Christer Halldin, Cathy L. Dantzman. Synthesis of a [2H6], [2H4], [11C] and [14C] Labeled Delta Opioid Agonist. 2011 Journal of Labeled Compounds and Radiopharmaceuticals: 54, 847-854

Hudzik, TJ, C. Maciag, M. A. Smith, Robert Caccese, Mark R Pietras, Khanh H Bui, Martin Coupal, Lynda Adam, Kemal Payza, Andrew Griffin, Gennady Smagin, Dekun Song, Michael Swedberg, and William F Brown. 2011. Preclinical pharmacology of AZ2327 - a highly selective agonist of the -opioid receptor. J. Pharmacol. Exp. Ther. 338 (1) : 195–204, 2011. Online doi:10.1124/jpet.111.179432.

Shenvi, A, Schooler, M. Hill, D; Bernstein, P; Warwick, P; Shen, L; Nugiel, D; Krumrine, D; Luo, X;, Blake, T; Sobotka-Briner, C; Brockel, B;, Moore, C;, Sutton, E; Condon, S; Zhang, M;, Hudzik, T;, Pierson, E; 2- Carboxamidochroman: An Orally Bioavailable 5-HT1B Receptor Antagonist. J. Medicinal Chemistry 1, 2010.

Simmons MA, Werkheiser JL, and Hudzik TJ (2010) Acute nicotine and phencyclidine increase locomotor activity of the guinea pig with attenuated potencies relative to their effects on rat or mouse. Pharmacology, Biochemistry, and Behavior 94(3):410-415.

Sydserff, S; Sutton, E; Song, D; Quirk, M; Maciag, C; Li, C; Jonak, G; Gurley, D; Gordon, J; Christian, E; Doherty, J; Hudzik, T; Johnson, E; Mrzljak, L; Piser, T; Smagin, G; Wang, Y; Widzowski, D; Smith, J. Selective α7 Nicotinic Receptor Activation by AZD0328 Enhances Cortical Dopamine Release and Improves Learning and Attentional Processes. Biochemical Pharmacology, 78 (7) 2009, pp 880-888, 2009.

Otieno, MA; Nicole Bavuso; Joseph Milano; Linda-Foster Brown; Khanh-Hui Bui; Yan Li; Thomas Hudzik; Debra Wescott; Calvert Louden; Martin Dyroff; Francois Pognan. Mechanistic Investigation of N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide -induced Insulin depletion in the rat and RINm5F Cells. Toxicological Sciences 2008, 105: 221-229.

Horchler, C; McCauley, JP. Snyder, DH; Moore, C; Hudzik, TJ; Chapdelaine, M. Synthesis of Novel Quinolone and Quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl) amides: A Late-Stage Diversification Approach to Potent 5HT1B Antagonists. Bioorganic & Medicinal Chemistry 15(2):939-50, 2007 Jan 15

Hudzik, TJ, Yanek, M, Porrey, T, Evenden J, Paronis, C, Mastrangelo, M, Ryan, C

Ross, S and Stenfors, C. Behavioral pharmacology of AR-A2, a novel 5-HT1B antagonist. J. Pharmacol. Exp. Ther., 304 (3), pp 1072-1084, 2003.

Peeling, J. Corbett, D, Marc R. Del Bigio, M, Hudzik, T, Campbell, M. and Palmer, G. Middle cerebral artery occlusion: correlations between histopathology T2-weighted MRI & behavioral indices. J. Stroke Cerebrovas. Dis. 10, P166-177, 2001.

Palmer, GC, Peeling, J, Corbett, D, DelBigio, MR and Hudzik, TJ. T2-Weighted MRI correlates with long term histopathology, neurology scores, and skilled motor behavior in a rat stroke model. Ann. NY Acad Sci 939: 283-296, 2001.

Tuor, U.I., T. Hudzik, K. Malisza, S.Sydserff, P. Kozlowski and M.R. Del

Bigio. Long term deficits following cerebral hypoxia-ischemia in four-week-old rats: Correspondence between behavioral, histological and magnetic resonance imaging assessments. Exp. Neurol. 167, pp 272-281, 001.

Hudzik, TJ, Howell, A. and Cross, A. Disruption of acquisition and performance of operant response-duration differentiation by unilateral nigrostriatal lesions. Behavioural Brain Research 114: 65-77, 2000.

Hudzik, TJ, Howell, A. and Cross, AJ. Antiparkinson potential of delta opioid receptor agonists. Eur J. Pharmacol. 396: 101-107, 2000.

Hudzik, TJ, A. Borrelli, P. Bialobok, D. Widzowski, S. Sydserff, A. Howell, P. Gendron,

D. Corbett, J. Miller, G.C. Palmer. Long-Term Functional Endpoints Following Middle Cerebral Artery Occlusion in the Rat: Rotation, Staircase Test and Operant Behaviors. Pharmacol. Biochem Behav. 65: 553-562, 2000.

Palmer G.C.; Cregan E.F.; Bialobok P.; Sydserff S.G.; Hudzik T.J.; McCarthy D.J.

The low-affinity use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke, Ann NY Acad. Sci 890:406-420, 1999.

Simmons, R.D., Kaiser, F. and Hudzik, T.J. Behavioral effects of AR-R 15849, a highly selective CCK-A agonist. Pharmacol. Biochem. Behav. 62: 549-557, 1999.

Palmer GC. Murray RJ. Cramer CL. Stagnitto ML. Knowles MK. Freedman LR. Eismann MS. Mahmood N. Balestra M. Borrelli AR. Hudzik TJ. McCarthy DJ. [S]-AR-R 15896AR-A novel anticonvulsant: acute safety, pharmacokinetic and pharmacodynamic properties. J. Pharmacol. Exp. Ther. 288(1):121-32, 1999 Jan.

Palmer, G.C., Robert J. Murray, Carrie L. Cramer, Mary L... Stagnitto, Marilyn K. Knowles, Lou R. Freedman, Mark S. Eismann, Nik Mahmood, Mike Balestra, Alfonso R. Borrelli, Thomas J. Hudzik, and Dennis J. McCarthy. [S, R phenyl-2-pyridine-ethanamine dihydrochloride selection of the [S] isomer

AR-R 15896AR, based on its anticonvulsant, acute safety, pharmacokinetic, and pharmacodynamic properties. J. Pharmacol. Exp. Ther. 288:121-132, 1999.

Kinney, GG. Griffiths, J.C. and Hudzik, TJ. Antidepressant-like effects of 5-hydroxytryptamine1A Receptor Agonists on Operant Responding under the Response Duration Differentiation Schedule. Behav. Pharmacol. 9: 309-318, 1998.

Palmer, G.C., Borrelli, AR, Hudzik, TJ, Sparber, S. Acute heat stress model of seizures in weanling rats: influence of prototypic anti-seizure compounds. Epilepsy Research 30: 203-217, 1998.

Borrelli, AR, Palmer, GC, Hudzik, TJ and Sparber. Evaluation of remacemide hydrochloride and prototype anticonvulsants in a rat model of febrile-induced seizures. SB. Epilepsia 38 (supp3), p 227, 1997.

Wenger, G.R., Hudzik, T. Moore, E. and Wright, D.W. Pentobarbital, diazepam and phencyclidine disrupt delayed matching performance: interactions with picrotoxin in pigeons and squirrel monkeys. Behav. Pharmacol. 7: 384-394, 1996.

Hudzik, TJ, Freedman, LS and Palmer, GC. Remacemide Hydrochloride and ARL 15896AR lack abuse potential: additional differences from other noncompetitive NMDA antagonists. Epilepsia: 37: 544-550, 1996.

Kinney, GG, Harris, E, Ray, R and Hudzik, TJ. 2-mediated inhibition of electrically-stimulated contraction of guinea pig lateral myenteric plexus. Eur. J. Pharmacol. 294: 547-553, 1995.

Hudzik, TJ and Palmer, GC. Effects of anticonvulsants on operant learning in rats: comparison of remacemide hydrochloride and FPL 15896AR to other anticonvulsant agents. Epilepsy Research 21: 183-193, 1995.

Hudzik, TJ and McMillan, DE. Drug effects on response duration differentiation IV: effects of trimethyltin. Neurotoxicology and Teratology 17:665-671, 1995.

Hudzik, TJ and McMillan, DE. Drug effects on response duration differentiation I: differential effects of drugs of abuse. Psychopharmacology, 114: 620-627, 1994.

Hudzik, TJ and McMillan, DE. Drug effects on response duration differentiation II: selective effects of antidepressant drugs. Journal of Pharmacology and Experimental Therapeutics, 268: 1335-1342, 1994.

Hudzik, TJ, DeCosta, B, and McMillan, DE. -Receptor mediated emetic response in pigeons: agonists, antagonists, and modifiers. European Journal of Pharmacology 236: 279-287, 1993.

Wenger, GR; Hudzik, TJ and Wright, DR. Titrating matching-to-sample performance in pigeons: effects of diazepam, morphine, and cholinergic agents, Pharmacology, Biochemistry and Behavior, 46(2):43543, 1993.

Hudzik, TJ and McMillan, DE. Effects of intravenous cocaine self-administration on ethanol intake in the rat. Drug and Alcohol Dependence, 33:225-234, 1993

Hudzik, TJ and Wenger, GR. Effects of drugs of abuse and cholinergic agents on delayed matching-to-sample responding in the squirrel monkey. Journal of Pharmacology and Experimental Therapeutics 265: 120-127, 1993.

Lyon, M., Hudzik, T., W. B. Lawson, W.B. and McMillan, D.E.

Potential animal model of increased etoh intake in schizophrenia: Prenatal d-amphetamine exposure vs. pair-feeding control conditions, Schizophrenia Research, 9: 243-244, 1993.

Hudzik, TJ Sigma ligand-induced emesis in the pigeon. Rapid Communication: Pharmacology, Biochemistry and Behavior 41:215-217, 1992.

Hudzik, TJ and Slifer, BL Interaction of sigma and PCP-like drugs on operant behavior in the rat. Psychopharmacology 108: 115-122, 1992.

Shellnut, S; McMillan, DE; Hudzik, TJ; and Lattin, C. The effects of cocaine and ethylcocaine on schedule-controlled behavior in the rat. Pharmacology, Biochemistry and Behavior 43: 509-511, 1992.

Hudzik, TJ and Slifer, BL Role of dopamine in the effects of pentazocine and tripelennamine. Pharmacology, Biochemistry and Behavior 36: 547-554, 1990.

Hudzik, TJ and Slifer, BL (1987) Effects of tripelennamine on the discriminative stimulus properties of opioids in the morphine-tolerant rat. Federation Proceedings 46: 1343, 1988.

Invited Presentations

TJ Hudzik: Intracranial Self-Stimulation as an alternative model for assessment of the reinforcing effects of drugs. Society of Toxicology, 3/2013.

TJ. Hudzik: SPS Webinar, Incorporation of abuse liability endpoints into toxicology studies, 3/2013.

K. Cannon and TJ Hudzik: IQ Consortium Webinar on modeling risk factors of suicidal behavior, 1/2013.

TJ Hudzik: Animal models of risk factors associated with suicidal behavior. American College of Toxicology, 2012.

TJ Hudzik: Thoughts on best practice for design of physical dependence studies. Safety Pharmacology Society, 2012.

TJ Hudzik: Assessment of abuse liability for new chemical entities. Applied Pharmaceutical Toxicology, 2012.

TJ Hudzik: The delta opioid receptor revisited. Rosalind Franklin Medical College Seminar speaker, 2012.

TJ Hudzik and K. Cannon (Chairs): Clinical and Preclinical Risk Factors Associated with Suicidal Behavior: A Neurobiological Perspective. Symposium at Society for Neuroscience, 2012.

TJ Hudzik: Pharmaceutical Drug Discovery and Development. University of Ohio Medical School, 2011.

Abstracts

Carla Maciag, Shuang Li, Mark Pietras, Jin Zhou, Joe McLaughlin, Linda Litwin, Carolann Thompson, Jennifer Werkheiser and TJ. Hudzik: Effects of the Delta Opioid Agonist AZD2327 in Tests for Anxiolytic and Antidepressant Activity. Presented at the Society for Neuroscience meeting, 2011.

J. L. Werkheiser, T. J. Hudzik: Synergistic interaction of escitalopram and traxoprodil in ketamine drug discrimination in the rat/ (presented at the Society for Neuroscience meeting, 2009.

S. LI, T. PISER, M. SMITH, T. HUDZIK, C. MACIAG, C. THOMPSON, J. MCLAUGHLIN, B. BROCKEL: Effects of prenatal stress and chronic antidepressant treatment on brain and plasma BDNF in rats. Society for Neuroscience Meeting, 2008.

Smagin, GN, Song, D, Medd, A., Cross, AJ, Hudzik, T, and Mrzljak, L.: Neurochemical validation of centrally active delta-opioid receptor agonists as novel treatment of anxiety disorders. ECNP 2008, Poster, Barcelona.

TJ Hudzik, Z. Zeller, J Zhou, B Brockel, EJ Sutton, CM Maciag, S Grimm, D. Widzowski: Further characterization of quetiapine and norquetiapine in rodent models of antidepressant and anxiolytic action: importance of route of administration. ECNP Meeting 2008.

C.M. Maciag, T. Porrey, TJ Hudzik: AZD0328, An α7 neuronal nicotinic receptor agonist, facilitates acquisition and performance of differential reinforcement of low rates (DRL) responding in fimbria-fornix lesioned rats. Society for Neuroscience Meeting 2007.

EJ Sutton, Tara Porrey, CM Maciag and TJ Hudzik: AZD0328, An α7 neuronal nicotinic agonist, potently facilitates the acquisition of operant responding in rats under conditions of delayed reinforcement. Society for Neuroscience Meeting 2007.

N. Spear, J. Liu, T. J. Hudzik, V. Chhaljlani, *L. A. Radov: The relationship of non-displaceable binding of agonists to the delta-opioid receptor and receptor desensitization. Soc. Neuroci. 2007. Poster

C. Maciag, J. Smolka, J. McLaughlin, TJ Hudzik, J. Evenden and D. Widzowski: Anxiolytic effects of quetiapine in rat punished responding: mechanism of action and the role of D2 antagonism. ECNP 2007.

Hudzik, T, Ray, R. and Borelli, A.: Comparative effects of sigma ligands: behavior and antihypoxia. Society for Neuroscience, San Diego, 2004.

Maciag, C, Lautenslager, T, Best, E, and Hudzik, T.: Benzodiazepines potently disrupt DRL responding in rats. Comparison of subtype-selective modulators to diazepam. Society for Neuroscience, San Diego 2004.

Macaig, C, Smolka, J, Duncan, B, Hudzik, T, Widzowski, D.: In search of the next generation of anxiolytics: how do they compare in efficacy vs cognitive side effects? Society for Neuroscience, New Orleans 2003.

Pietras, M, Maciag, C., Smolka, J, Hudzik, T., Bialecki, R.: A comparison of diazepam with next generation anxiolytics; margins for adverse changes in coordinated and spontaneous motor activity. Society for Neuroscience, New Orleans 2003.

Hudzik, T., Smolka, J. Litwin, L. Porrey, T and Pierson, E.: In vivo pharmacology of AZD1134, a novel 5-HT1B antagonist. ENCP 2003.

Hudzik, T, Yanek, M, Porrey, T, Evenden, J, Mastrangelo, M, Ryan, C, Ross, S, Stenfors, C.: Preclinical antidepressant profile of AR-A000002, a novel 5-HT1B antagonist. International J. Neuropsychopharmacol. 5: S100, 2002.

Hudzik, T, Yanek, M, Porrey, T, Mastrangelo, M, Ryan, C, Paronis, C, Ross, S, Stenfors, C.: Evaluation of the anxiolytic protential of AR-A000002, a novel 5-HT1B antagonist. International J. Neuropsychopharmacol. 5: S100, 2002.

Hudzik, TJ; M. Yanek and M. Mastrangelo: Characteristics and species generality of the antidepressant effect upon response duration

Contact this candidate